{"id":62230,"date":"2026-04-02T23:13:42","date_gmt":"2026-04-02T15:13:42","guid":{"rendered":"https:\/\/flcube.com\/?p=62230"},"modified":"2026-04-02T23:13:43","modified_gmt":"2026-04-02T15:13:43","slug":"remegen-secures-nmpa-approval-for-phase-i-iia-trial-of-bispecific-adc-rc288-targeting-psma-and-b7h3-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62230","title":{"rendered":"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors"},"content":{"rendered":"\n<p><strong>RemeGen Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>) announced it has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>Phase I\/IIa clinical study<\/strong> evaluating <strong>RC288<\/strong>, a <strong>bispecific antibody-drug conjugate (ADC)<\/strong> targeting <strong>PSMA and B7H3<\/strong>, in patients with <strong>locally advanced unresectable or metastatic malignant solid tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-framework\">Clinical Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>RC288<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Bispecific antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>PSMA (prostate-specific membrane antigen) and B7H3<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase I\/IIa<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced unresectable or metastatic malignant solid tumors<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Next-generation conjugation and toxin technologies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dual-target-mechanism-of-action\">Dual-Target Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-psma-prostate-specific-membrane-antigen\">PSMA (Prostate-Specific Membrane Antigen)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Characteristic<\/strong>: Type II transmembrane glycoprotein<\/li>\n\n\n\n<li><strong>Tumor Function<\/strong>: Supports tumor growth and angiogenesis<\/li>\n\n\n\n<li><strong>Expression Profile<\/strong>: Overexpressed in multiple solid tumor types beyond prostate cancer<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Enables targeted delivery of cytotoxic payload to tumor vasculature and cells<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-b7h3-immune-checkpoint-molecule\">B7H3 (Immune Checkpoint Molecule)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Function<\/strong>: Immune checkpoint regulator<\/li>\n\n\n\n<li><strong>Tumor Role<\/strong>: When overexpressed in tumor tissues, promotes immune evasion and tumor progression<\/li>\n\n\n\n<li><strong>Therapeutic Advantage<\/strong>: Dual targeting addresses both direct tumor killing and immune microenvironment modulation<\/li>\n\n\n\n<li><strong>Resistance Mitigation<\/strong>: Simultaneous targeting may overcome single-target resistance mechanisms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-innovation\">Technology Innovation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-generation-platform-features\">Next-Generation Platform Features<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Advanced Conjugation Chemistry<\/strong>: Enhanced drug-to-antibody ratio (DAR) control and stability<\/li>\n\n\n\n<li><strong>Novel Toxin Payloads<\/strong>: Potent cytotoxic agents optimized for solid tumor penetration<\/li>\n\n\n\n<li><strong>Bispecific Architecture<\/strong>: Single molecule capable of simultaneous dual-target engagement<\/li>\n\n\n\n<li><strong>Manufacturing Process<\/strong>: Proprietary production methods ensuring consistent quality and yield<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Targeting Approach<\/strong>: Addresses complementary tumor survival pathways<\/li>\n\n\n\n<li><strong>Solid Tumor Focus<\/strong>: Specifically designed for challenging solid tumor microenvironment<\/li>\n\n\n\n<li><strong>Platform Scalability<\/strong>: Technology applicable to other bispecific ADC combinations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-significance\">Scientific Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Target Combination<\/strong>: First-in-class approach combining PSMA and B7H3 targeting<\/li>\n\n\n\n<li><strong>Mechanistic Synergy<\/strong>: Simultaneous attack on tumor growth pathways and immune evasion mechanisms<\/li>\n\n\n\n<li><strong>Broad Applicability<\/strong>: Potential across multiple PSMA\/B7H3 co-expressing solid tumor types<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-opportunities\">Commercial Opportunities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Medical Need<\/strong>: Addresses treatment-resistant locally advanced and metastatic solid tumors<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success would validate RemeGen&#8217;s next-generation ADC technology<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Dual-target approach may have international regulatory and commercial appeal<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Growth<\/strong>: Antibody-drug conjugates represent one of biopharma&#8217;s fastest-growing therapeutic modalities<\/li>\n\n\n\n<li><strong>Bispecific Trend<\/strong>: Industry shift toward multi-targeting approaches to improve efficacy and overcome resistance<\/li>\n\n\n\n<li><strong>Chinese Innovation<\/strong>: Demonstrates China&#8217;s growing capability in complex biologic development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development plans, mechanism of action, and commercial potential. Actual results may differ due to clinical trial outcomes, safety findings, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040104281_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040104281_c.\"><\/object><a id=\"wp-block-file--media-8fdcc7b5-a1cd-4986-99b7-535ac0a302f7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040104281_c.pdf\">2026040104281_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040104281_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8fdcc7b5-a1cd-4986-99b7-535ac0a302f7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Ltd (HKG: 9995) announced it has received approval from China&#8217;s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,1155,375],"class_list":["post-62230","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-hkg-9995","tag-remegen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Ltd (HKG: 9995) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a Phase I\/IIa clinical study evaluating RC288, a bispecific antibody-drug conjugate (ADC) targeting PSMA and B7H3, in patients with locally advanced unresectable or metastatic malignant solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62230\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"RemeGen Ltd (HKG: 9995) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a Phase I\/IIa clinical study evaluating RC288, a bispecific antibody-drug conjugate (ADC) targeting PSMA and B7H3, in patients with locally advanced unresectable or metastatic malignant solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62230\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T15:13:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T15:13:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62230#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62230\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Secures NMPA Approval for Phase I\\\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors\",\"datePublished\":\"2026-04-02T15:13:42+00:00\",\"dateModified\":\"2026-04-02T15:13:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62230\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9995\",\"RemeGen\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62230#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62230\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62230\",\"name\":\"RemeGen Secures NMPA Approval for Phase I\\\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-02T15:13:42+00:00\",\"dateModified\":\"2026-04-02T15:13:43+00:00\",\"description\":\"RemeGen Ltd (HKG: 9995) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a Phase I\\\/IIa clinical study evaluating RC288, a bispecific antibody-drug conjugate (ADC) targeting PSMA and B7H3, in patients with locally advanced unresectable or metastatic malignant solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62230#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62230\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62230#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Secures NMPA Approval for Phase I\\\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Ltd (HKG: 9995) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a Phase I\/IIa clinical study evaluating RC288, a bispecific antibody-drug conjugate (ADC) targeting PSMA and B7H3, in patients with locally advanced unresectable or metastatic malignant solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62230","og_locale":"en_US","og_type":"article","og_title":"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors","og_description":"RemeGen Ltd (HKG: 9995) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a Phase I\/IIa clinical study evaluating RC288, a bispecific antibody-drug conjugate (ADC) targeting PSMA and B7H3, in patients with locally advanced unresectable or metastatic malignant solid tumors.","og_url":"https:\/\/flcube.com\/?p=62230","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-02T15:13:42+00:00","article_modified_time":"2026-04-02T15:13:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62230#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62230"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors","datePublished":"2026-04-02T15:13:42+00:00","dateModified":"2026-04-02T15:13:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62230"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","HKG: 9995","RemeGen"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62230#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62230","url":"https:\/\/flcube.com\/?p=62230","name":"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-02T15:13:42+00:00","dateModified":"2026-04-02T15:13:43+00:00","description":"RemeGen Ltd (HKG: 9995) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a Phase I\/IIa clinical study evaluating RC288, a bispecific antibody-drug conjugate (ADC) targeting PSMA and B7H3, in patients with locally advanced unresectable or metastatic malignant solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62230#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62230"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62230#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Secures NMPA Approval for Phase I\/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62230"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62230\/revisions"}],"predecessor-version":[{"id":62233,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62230\/revisions\/62233"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}